The IL-23/Th17 axis plays a central role in the development of psoriasis (Hawkes et al., 2017), some biologics (IL-17 antagonists: Secukinumab, Ixekizumab, and Brodalumab; IL-23 antagonists: Risankizumab, Guselkumab, and Tildrakizumab) focus on this signaling pathway have been used for the treatment of moderate-severe psoriasis (Sharma et al., 2022). This evidence concerns the gene IL17A and psoriasis.